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Introduction. Several biomedical findings have established the effects of hypertension on haemostasis and roles of blood
coagulation products in the clinical course of hypertension. Methods. This cross-sectional study aimed at determining effects of
hypertension on prothrombin time (PT) and activated partial thromboplastin time (APTT) in hypertensive patients in comparison
with normotensive subjects attending a tertiary hospital in Calabar. Forty-two (42) hypertensive patients and thirty-nine (39)
normotensive control subjects were investigated for PT and APTT using Quick one-stage methods. Results. Systolic blood pressure
(SBP) and diastolic blood pressure (DBP) correlated positively with APTT (𝑟 = 0.3072, 𝑟 = 0.4988; 𝑃 < 0.05) in hypertensive
patients. DBP, SBP, PT, and APTT were significantly higher in hypertensive patients when compared to normotensive subjects
(𝑃 < 0.05). DBP correlated negatively with duration of illness (𝑟 = −0.3097; 𝑃 < 0.05) in hypertensive patients and positively
with age of normotensive subjects (𝑟 = 0.3523; 𝑃 < 0.05). Conclusion. The results obtained indicated that measurements of PT
and APTT may serve as indices for evaluating hemostatic abnormalities in hypertensive patients and guide for antihypertensive
therapy. However, to have better understanding of hemostatic activities in hypertension, it is recommended to conduct D-dimer,
platelet factors, and protein assays.
1. Introduction
Cardiovascular diseases account for about one-third of pre-
mature deaths inmen and one-quarter in women and arterial
hypertension is one of the most significant risk factors
for cardiovascular diseases [1]. Despite current knowledge,
extensive clinical and experimental research, the cause of
hypertension remains unknown in about 95% of all cases
[1]. Hypertension is a chronic medical condition in which
the blood pressure is indisputably elevated (≥140/90mmHg).
It is one of the most common worldwide diseases afflict-
ing humans. Globally cardiovascular disease accounts for
approximately 17 million deaths a year, nearly one-third of
the total. Of these, complications of hypertension account
for 9.4 million deaths worldwide every year. Hypertension is
responsible for at least 45% of deaths due to heart disease [2].
Due to several associated morbidity, mortality, and economic
cost to society, hypertension is now a serious public health
challenge to both developed and developing nations [3, 4].
According to recent epidemiologic data, the overall
prevalence of 28% of the general population is suffering from
hypertension in Sub-Saharan Africa, the prevalence rate in
Nigeria is put at 22% with steady annual increase [5].
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Hypertension is classified as either primary or secondary.
It is primary when no medical cause can be found to explain
the raised blood pressure. This type represents between 90
and 95% of hypertension cases [6]. Secondary hypertension
represents approximately 10% of all hypertension cases.
Identifiable underlying causes of secondary hypertension are
kidney disease, renal hyperaldosteronism, and pheochromo-
cytoma. Secondary hypertension has specific therapy; it is
potentially curable and often distinguishable from primary
one on clinical grounds [7].
Risk factors associated with hypertension include age,
race, family history, obesity, sedentary lifestyle, alcohol abuse,
and stress among others. Hypertension increases hardening
of the arteries and predisposes individuals to heart disease,
peripheral vascular disease, and strokes [7–10].
Hypertensive patients are at high risk for the develop-
ment of cardiovascular diseases [11], whereas several studies
have shown that treatment of hypertension diminishes the
prevalence of cardiovascular diseases [12–14]. The existence
of hypertension, especially in combination with other risk
factors, is disadvantageous for the prognosis of cardiovascu-
lar diseases [15]. The integrity of the blood vessels is essential
because damage of the intima, which may occur in hyperten-
sion, can finally cause atherosclerosis. This kind of patient is
likely to develop increased platelet aggregationwith heart and
blood vessel problems as possible sequelae [16]. Moreover,
blood vessel damage activates the coagulation system, which
may also stimulate the progress of atherosclerosis.
Coagulation abnormalities in pregnant women have been
reported to be more serious in women with hypertension
(preeclampsia) than in those without hypertension [17].
In patients with borderline hypertension, even before the
appearance of clinical manifestations of vascular damages
[18], coagulation activation seems to be already present [18].
Besides platelet aggregability and coagulation activation,
fibrinolysis, that is, plasma tissue-type plasminogen activator
activity, appears to be a major factor related to the risk of
cardiovascular disease [19–22].
Prothrombin time (PT) and activated partial thrombo-
plastin time (APTT) have been shown to be associated with
elevated systolic and diastolic blood pressures in hypertensive
and normotensive patients [23]. In a studywhich involved the
inclusion of one hundred and one patients with hypertension
of mild to moderate grades, attending Al-Najaf Teaching
Hospital, Iraq, significant differences were found in PT and
APTT between hypertensive and normotensive patients [24].
The prothrombin time (PT) and its derived measures of
prothrombin ratio (PR) and international normalized ratio
(INR) are measures of the extrinsic pathway of coagulation.
The APTT in contrast to the PT measures the activity of
the intrinsic pathways of coagulation. Endothelial damage,
platelet hyperactivity, and other changes of blood coagulation
may play a role in the vascular complications of essential
hypertension [25–27].
Themain aim of this study is to assess possible association
between prothrombin time and activated partial thrombo-
plastin time with effects of blood pressures in hypertensive
and normotensive subjects and their significant utility for
screening hemostatic dysfunction in hypertensive patients.
2. Materials and Methods
2.1. Study Area. The study was conducted at the University
of Calabar Teaching Hospital, Calabar, Cross River State.
Calabar is the capital city of Cross River State which is
divided into Calabar Municipal and Calabar South Local
Governments and is located at the coastal southeastern area
(4∘57󸀠N 8∘19󸀠E) of Nigeria. It has an area of 604 km2 and a
population of 371,022 at the 2006 census.
2.2. Study Population. A total of eighty-onesubjects were
enrolled into the study. Forty-two (42) hypertensive patients
aged between 30 and 80 years and thirty-nine (39) normoten-
sive control subjectswere investigated for PT andAPTTusing
Quick one-stage methods.The selection of patients was done
with the support of the physician and nursing staff of the
Medical Outpatient Department (MOPD) of University of
Calabar TeachingHospital (UCTH), Calabar.The procedures
employed consisted of a questionnaire interview, taking of
patient’s history, and blood pressure measurement.
2.3. Inclusion Criteria for Hypertensive Patients. The inclu-
sion criteria are as follows:
(i) the presence of the history of primary hypertension;
(ii) elevated blood pressure (≥140/90mmHg);
(iii) no history of administration of anticoagulant therapy;
(iv) no history of chronic viral infection and/or liver
diseases (HBV,HCV,HIV, and alcohol consumption);
(v) having not been on long-term drug regimen;
(vi) must be within normal range body mass index;
(vii) being with no trace of underlying causes.
2.4. Exclusion Criteria for Hypertensive Patients. The exclu-
sion criteria are as follows:
(i) the absence of family history of primary hyperten-
sion;
(ii) normal blood pressure (<140/90mmHg);
(iii) those on anticoagulant therapy;
(iv) those with chronic viral infections and/or liver dis-
eases such as HBV, HCV, HIV, and alcoholism;
(v) obese individuals.
2.5. Inclusion Criteria for Normotensive Control Subjects. The
inclusion criteria are as follows:
(i) the absence of family history of hypertension;
(ii) normal blood pressure (<140/90mmHg);
(iii) no history of administration of anticoagulant therapy;
(iv) no history of chronic viral infection and/or liver
diseases (HBV,HCV,HIV, and alcohol consumption);
(v) having not been on long-term drug regimen;
(vi) must be within normal body mass index;
(vii) with no trace of underlying causes.
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2.6. ExclusionCriteria forNormotensive Control Subjects. The
exclusion criteria are as follows:
(i) the presence of family history of hypertension;
(ii) elevated blood pressure (≥140/90mmHg);
(iii) the absence of family history of primary hyperten-
sion;
(iv) normal blood pressure (<140/90mmHg);
(v) those on anticoagulant therapy;
(vi) those with chronic viral infections and/or liver dis-
eases such as HBV, HCV, HIV, and alcoholism;
(vii) obese individuals.
2.7. Ethical Clearance and Informed Consent. The ethical
clearance was obtained from the Ethical Committee of
UCTH,Calabar, Cross River State, Nigeria. Informed consent
was obtained from all participating subjects. This was done
via an informed consent form duly completed by all the
subjects.
2.8. Questionnaire. Semistructured administered question-
naires were used to obtain data such as age, marital status,
clinical signs and symptoms, and provisional diagnosis.
2.9. Sample Collection. Four and a half-millilitres (4.5mL)
of blood sample was drawn from hypertensive and nor-
motensive subjects and discharged into a 0.5mL of 3.13%
trisodium citrate sample bottle. The anticoagulated samples
were centrifuged at 4000 rpm for 10 minutes and platelet
poor plasma stored in a deep freezer at −20∘C until assayed.
Standard method of Quick one-stage analysis by [28] was
used for PT and APTT.
2.10. Statistical Method. The generated data was systemati-
cally analysed as appropriate for means, standard deviation,
Student’s 𝑡-test, Pearson’s correlation analysis, and analysis
of variance on Microsoft Excel and SPSS software version
18 (California Inc.). Results were presented as the mean ±
standard deviation. A two-sided 𝑃 < 0.05 was considered
statistically significant for 𝑡-test (used to determine the
differences between the groups) and Pearson’s correlation
analysis was used to determine the intervariable associations
of the various groups.
3. Results
Table 1 shows the mean and standard deviation for the sys-
tolic pressure, diastolic pressure, prothrombin time test, and
activated partial thromboplastin time test of hypertensives
and normotensives including the duration of hypertensive
subjects enrolled in the study. The mean and standard
deviation for systolic blood pressure, diastolic blood pres-
sure, prothrombin time test, activated partial thromboplastin
time test, and duration of hypertensives were 157.02 ±
18.78mmHg, 95.12 ± 13.00mmHg, 14.45 ± 1.97 seconds,
35.43±5.05 seconds, and 4.06±5.93 years, respectively, while
Table 1: Mean systolic pressure, diastolic pressure, prothrombin
time test (PTT), and partial thromboplastin time test kaolin (PTTK)
of hypertensive patients (test) and normotensive subjects (control)














pressure (mmHg) 157.02 ± 18.77 117.66 ± 11.65 𝑃 < 0.05
Diastolic blood
pressure (mmHg) 95.11 ± 12.99 79.16 ± 10.99 𝑃 < 0.05
PTT (seconds) 14.45 ± 1.96 13.60 ± 1.19 𝑃 < 0.05
PTTK (seconds) 35.42 ± 5.04 32.56 ± 3.23 𝑃 < 0.05
Student’s 𝑡-test analysis.
𝑃 < 0.05 is significant.
𝑃 < 0.05 is not significant.
𝑛
1
= number of hypertensive patients.
𝑛
2
= number of normotensive subjects.
Table 2: Comparison of the prothrombin time test (PTT) and
partial thromboplastin time test kaolin (PTTK) based on duration of


















(seconds) 14.28 ± 1.80 15.00 ± 2.67 14.50 ± 1.87 𝑃 > 0.05
PTTK
(seconds) 34.89 ± 4.57 37.37 ± 6.07 35.33 ± 6.05 𝑃 > 0.05
Analysis of variance.
𝑃 < 0.05 is significant.
𝑃 < 0.05 is not significant.
𝑛
1
= number of hypertensive patients with duration of illness ≤3 years.
𝑛
2
= number of hypertensive patients with duration of illness 4–7 years.
𝑛
3
= number of hypertensive patients with duration of illness ≥8 years.
the mean and standard deviation for the systolic pressure,
diastolic pressure, prothrombin time test, and activated par-
tial thromboplastin time test of normotensives studied were
117.67 ± 11.65mmHg, 79.17 ± 10.99mmHg, 13.60 ± 1.19
seconds, and 32.57 ± 3.23 seconds, respectively.
Diastolic blood pressures, systolic blood pressures, Pro-
thrombin Time Test and Activated Partial Thromboplastin
Time Test were significantly higher in hypertensive patients
when compared to normotensives (𝑃 < 0.05).
Based on the duration of hypertension, the hypertensive
patients were grouped into three different groups (≤3 years,
4–7 years, and ≥8 years); their prothrombin time was 14.28 ±
1.80, 15.00±2.67, and 14.50±1.87 seconds, respectively, while
their activated partial thromboplastin time was 34.89 ± 4.57,
37.37 ± 6.07, and 35.33 ± 6.05 seconds, respectively, as shown
in Table 2.
Systolic blood pressure correlated positively with PTTK
(𝑟 = 0.3072; 𝑃 < 0.05) (Figure 4) and with diastolic
blood pressure (𝑟 = 0.4988; 𝑃 < 0.05) (Figure 2) in
hypertensive patients, respectively. Diastolic blood pressure
correlated negatively with duration of illness (𝑟 = −0.3097;
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Figure 1: Correlation plot of diastolic blood pressure against dura-
tion of illness in hypertensive patients.
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Systolic blood pressure (mmHg)
Figure 2:Correlation plot of systolic bloodpressure against diastolic
blood pressure in hypertensive patients.
𝑃 < 0.05) in hypertensive patients (Figure 1) and positively
with age (𝑟 = 0.3523; 𝑃 < 0.05) in normotensive subjects
(Figure 5). A positive correlation was observed between PTT
and PTTK both in hypertensive patients (𝑟 = 0.6217; 𝑃 <
0.05) (Figure 3) and in normotensive subjects (𝑟 = 0.5886;
𝑃 < 0.05) (Figure 6). More so positive correlation of systolic
and diastolic blood pressure of normotensive subjects was
observed across gender distribution (Figure 8) but negative
correlation between systolic blood pressure and male hyper-
tensive subjects (Figure 7).There was a statistical relationship
between PT and APTT and age of hypertensive patients (𝑃 <
0.05) (Table 3). However there was no statistical relationship
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Figure 4: Correlation plot of PTTK against systolic blood pressure
in hypertensive patients.
4. Discussion
Haemostatic system is directly involved in the atherosclerotic
process. Hypertension is an atherosclerotic risk factor caus-
ing endothelial dysfunction; therefore, endothelial damage,
platelets hyperactivation, and drugs are involved in the
coagulation and fibrinolytic system [29, 30]. Prothrombin
time and activated partial thromboplastin time are important
clinical parameters for assessing extrinsic and intrinsic fac-
tors/pathways of the coagulation system [30].
The findings of this study show significant increases in
the prothrombin time and activated partial thromboplastin
time of hypertensive patients when compared to those of
the normotensives (control). This increase could be due to
endothelial damage as a result of atherosclerosis caused by
hypertension on these patients (𝑃 < 0.05) [31].
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Figure 6: Correlation plot of PTTK against PTT in normotensive
subjects.
Theprothrombin time and activated partial thromboplas-
tin time of hypertensive patients increase with increase in
duration of hypertension which may be due to prolonged
endothelial wall effect as this will lead to sustained release
of vasoactive substances that interfere coagulation cascades,
and these indices eventually decrease as the antihypertensive
therapy continues, even lower than before they started treat-
ment; this finding is in consonance with Lee’s work and that
of Mirsaiedi et al. [32, 33].
There was a positive correlation between systolic pressure
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Figure 7: Correlation of systolic and diastolic blood pressure of
hypertensive subjects across gender distribution. Purple lines and
points: females. Blue line and points: males. Green line and points:
females. Yellow line and points:males. Number ofmale hypertensive
subjects (𝑛) = 16. Number of female hypertensive subjects (𝑛) = 26.
Table 3: Comparison of the prothrombin time test (PTT) and
partial thromboplastin time test kaolin (PTTK) across ages of


















(seconds) 13.80 ± 1.92 15.00 ± 1.96 14.26 ± 1.98 𝑃 < 0.05
PTTK
(seconds) 32.60 ± 4.39 38.29 ± 3.60 34.3 ± 5.29 𝑃 < 0.05
Analysis of variance.
𝑃 < 0.05 is significant.
𝑃 < 0.05 is not significant.
𝑛
1
= number of hypertensive patients with age range ≤35 years.
𝑛
2
= number of hypertensive patients with age range 36–50 years.
𝑛
3
= number of hypertensive patients with age range ≥51 years.
patients which could be due to the risk factors associated
with hypertension, for example, atherosclerosis, endothelial
dysfunction and antihypertensive drugs [34, 35].
There was a negative correlation between diastolic pres-
sure and duration of illness and a probable explanation to
this could be that reduced exposure of the vascular walls
to pressure in those with lower duration will give a higher
pressure than those who have higher exposure to this tension
because their blood vessels might be weaker and cannot exert
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Figure 8: Correlation of systolic and diastolic blood pressure of
normotensive subjects across gender distribution. Purple lines and
points: females. Blue line and points: females. Green line and points:
males. Red line and points: males. Number of male normotensive
subjects (𝑛) = 15. Number of female normotensive subjects (𝑛) = 15.
Table 4: Comparison of the prothrombin time test (PTT) and
partial thromboplastin time test kaolin (PTTK) across ages of


















(seconds) 13.75 ± 1.24 13.00 ± 1.154 13.86 ± 1.069 𝑃 > 0.05
PTTK
(seconds) 29.19 ± 8.06 27.14 ± 10.75 32.71 ± 4.46 𝑃 > 0.05
Analysis of variance.
𝑃 < 0.05 is significant.
𝑃 < 0.05 is not significant.
𝑛
1
= number of normotensive patients with age range ≤35 years.
𝑛
2
= number of normotensive patients with age range 36–50 years.
𝑛
3
= number of normotensive patients with age range ≥51 years.
resistance or pressure against blood flow when compared to
those with lower duration [35–38].
Positive correlation of systolic and diastolic blood pres-
sure of normotensive subjects was observed across gender
distribution, but negative correlation between systolic blood
pressure in male hypertensive subjects; these findings are in
conformity with previous studies [38–41]. There was a statis-
tical relationship between PT and APTT and age distribution
of hypertensive patients (𝑃 < 0.05); this supports the findings
of Akputuzor et al. and Mirsaiedi et al. [33, 42]. Prolonged
PT and APTT were common with elderly hypertensive
subjects; one could speculate that this phenomenon is due
to diminished prostacyclin synthesis and/or release by the
endothelial cells during old age.
Due to the fact that there was significant increase in
prothrombin time and activated partial thromboplastin time
of hypertensive patients when compared with normotensive
(control) subjects, assessment of these parameters may serve
as prognostic indices for evaluating hypertensive patients in
whom there was clinical evidence of hemostatic abnormality
and guide for antihypertensive therapy. However, to have
complete understanding of hemostatic activities in hyperten-
sion, it is recommended to conduct D-dimer, platelet factors,
and protein assays.
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